Alnylam Pharmaceuticals Inc ALNY

Alnylam Pharmaceuticals Inc is a biopharmaceutical company that focuses on RNA interference (RNAi) research to develop treatments for patients suffering from chronic diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. It operates internationally and has locations in the UK, Germany, Italy, Sweden, Japan and Brazil.

The company’s products include therapeutics targeting genetic diseases such as cardio-metabolic and central nervous system disorders, which includes ocular diseases. Alnylam Pharmaceuticals also produces medicines for hepatic infectious diseases. Brand names include ONPATTRO, a lipid complex injection targeting polyneuropathy of hereditary transthyretin-mediated amyloidosis; GIVLAARI for the treatment of acute haptic porphyria; and OXLUMO for patients suffering from PH1 (primary hyperoxaluria). Pipeline developments include givosiran for the treatment AHP in adolescent patients and patisiran for the treatment of transthyretin amyloidosis.

Alnylam Pharmaceuticals has a strategic agreement with Regeneron Pharmaceuticals, Inc., a biopharmaceuticals organisation based in New York. This company researches and manufactures products such as EYLEA for wet age-related macular degeneration and diabetic macular oedema. It also markets treatments for diseases such as myopic choroidal neovascularisation and diabetic retinopathy. The partnership is aimed at developing and commercializing a range of RNAi therapeutics. Alnylam Pharmaceuticals trades on the NASDAQ under the ALNY ticker.

Diversify your eToro virtual portfolio with ALNY stock today.